Alternatives to Alithea Genomics

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

A vertically-integrated procurement platform for the life sciences industry.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

AI-enabled technology for cell biology research and biopharma development.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Global supplier of life science research tools, including antibodies, reagents, and assays.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

AI-powered knowledge discovery for life sciences.

AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

Developing oral small molecule medicines for immunological and chronic diseases.

Revolutionizing genomic analysis with innovative sequencing technology.

Pioneering vision restoration therapies for severe retinal degenerations.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

Advancing next-generation mRNA medicines.

Developing novel therapies to reverse aging and extend lifespan.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

AI biologist platform accelerating preclinical drug development by integrating biological data for smarter decisions.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Scalable, one-time curative in-vivo gene editing therapies.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Platform designed to cut cell and gene therapy production costs.

Develops and distributes bioreactor technology for stem cell cultivation.

Decoding the immune system to pioneer a paradigm shift in disease diagnosis and treatment.

AI-driven biotechnology company developing novel protein therapeutics through generative biology.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Space BioTech startup developing an autonomous, high-throughput screening platform for drug discovery in microgravity.

Developing and manufacturing laminin-based cell culture substrates for advanced cell therapies and drug discovery.

Developing precision medicines for inflammatory and immune-mediated diseases using AI and patient sample analysis.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Advancing biopsy specimen stewardship and expanding access to precision oncology.

Developing disease-responsive advanced therapies through programmable gene control technology.

Developing human microbiology models for drug discovery.

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.

Developing an automated platform for liquid biopsy sample preparation.

AI-driven predictive modeling company focused on biology and life sciences.

Developer of spatial biology tools for life sciences research, now part of Bruker Spatial Biology.

AI safety and research company building reliable, interpretable, and steerable AI systems.

Building General Biological Intelligence

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

BreezeBio is a genetic medicine company developing a pipeline of precision therapeutics.

Developing novel immunotherapies and diagnostics for cancer.